Pregabalin and the Risk for Opioid-Related Death: A Nested Case–Control Study

See also: Editorial comment (page 727).

Note: The funding source had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Mr. Greaves had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Disclaimer: The opinions, results, and conclusions reported here are those of the authors and are independent from those of the funding sources. No endorsement by the Institute for Clinical Evaluative Sciences or the Ontario Ministry of Health and Long-Term Care is intended or should be inferred. The analyses, conclusions, opinions, and statements expressed here are those of the authors and not necessarily those of the Canadian Institute for Health Information.

Acknowledgment: The authors thank Brogan Ottawa for use of their drug product and therapeutic class database and the Canadian Institute for Health Information, which compiled and provided data and information on which parts of this report are based.

Grant Support: From the Ontario Ministry of Health and Long-Term Care (06673).

Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M18-1136.

Reproducible Research Statement:Study protocol and statistical code: Available from Dr. Gomes (e-mail, gomest@smh.ca). Data set: Available to those who meet prespecified criteria for confidential access at www.ices.on.ca/DAS.